APEXUS SELECTED TO CONTINUE AS THE HRSA 340B PRIME VENDOR

Apexus Selected to Continue as the HRSA 340B Prime Vendor

Irving, TX – January 8, 2020 – Apexus, LLC, is pleased to announce it has been selected by the Health Resources & Services Administration (HRSA) to continue as the 340B Prime Vendor. HRSA chose Apexus as part of a competitive, open bid process. The contract became effective Dec. 31, 2019.

“We are pleased and grateful to be selected to continue as the HRSA 340B Prime Vendor,” said Chris Hatwig, MS, RPh, FASHP, Apexus President. “As the HRSA 340B Prime Vendor, Apexus has a long history of collaborating with our partners in delivering lower drug pricing, 340B training and education programming, and technical support to all 340B stakeholders.”

The 340B Drug Pricing Program is a federal program that provides covered outpatient drugs to enrolled covered entities. More information about the 340B Drug Pricing Program is located here.

The 340B Prime Vendor Program is available at no cost to all eligible entities and requires registration with Apexus. Learn more or enroll in the 340B Prime Vendor Program, managed by Apexus.

About Apexus
Apexus serves as HRSA’s Prime Vendor for the 340B Drug Pricing Program. We provide access to discounted medications, education and compliance needs and manufacturer refund services to more than 12,200 covered entities serving vulnerable populations. More information about the Prime Vendor Program is available at www.340BPVP.com.